Homeland Insurance Company of New York v. Clinical Pathology Laboratories, Inc.

District Court, W.D. Texas·Decided October 19, 2022·No. 1:20-cv-00783·Unknown

Opinion

UNITED STATES DISTRICT COURT WESTERN DISTRICT OF TEXAS AUSTIN DIVISION

HOMELAND INSURANCE § COMPANY OF NEW YORK, § Plaintiff, § § v. § CIVIL NO. 1-20-CV-783-RP

§ CLINICAL PATHOLOGY § LABORATORIES, INC. and § SONIC HEALTHCARE USA, § Defendants.

REPORT AND RECOMMENDATION OF THE UNITED STATES MAGISTRATE JUDGE

TO: THE HONORABLE ROBERT PITMAN UNITED STATES DISTRICT JUDGE Before the Court are Homeland Insurance Company of New York’s Motion for Leave to File Third Amended Complaint and First Amended Answer, filed August 12, 2022 (Dkt. 131); Defendants’ Response to Homeland Insurance Company of New York’s Motion for Leave to File Amended Pleadings, filed August 26, 2022 (Dkt. 139); and Homeland Insurance Company of New York’s Reply in Support of Its Motion for Leave File Amended Pleadings, filed on October 3, 2022 (Dkt. 150).1 By Text Order entered October 4, 2022, the District Court referred the Motion to the undersigned Magistrate Judge for a report and recommendation, pursuant to 28 U.S.C. § 636(b)(1)(B), Federal Rule of Civil Procedure 72, and Rule 1(d) of Appendix C of the Local Rules of the United States District Court for the Western District of Texas.

1 The Court quotes redacted versions of Homelands’ briefs, which are filed under seal. 1 I. Procedural Background2 On July 24, 2020, Homeland Insurance Company of New York (“Homeland”) filed this insurance coverage lawsuit against Clinical Pathology Laboratories, Inc. (“CPL”), Sonic Healthcare USA, Inc. (“Sonic USA”), MedLab Pathology (“MedLab”), Sonic Healthcare (Ireland) Limited (“Sonic Ireland”), and Sonic Healthcare Limited (“Sonic”) (collectively, “Defendants”),

seeking a declaratory judgment that it has no duty to reimburse Defendants for defending a medical negligence lawsuit in Ireland arising out of Ireland’s CervicalCheck Program. Dkt. 1. On October 12, 2020, Homeland filed its 45-page Amended Complaint, asserting additional claims of negligent misrepresentation, breach of warranty, and reformation. Dkt. 21. Defendants moved to dismiss under Federal Rules of Civil Procedure 12(b)(2) and 12(b)(6). Dkt. 24. The District Court granted in part and denied in part the Motion to Dismiss. The District Court dismissed MedLab, Sonic Ireland, and Sonic for lack of personal jurisdiction under Rule 12(b)(2), and dismissed Homeland’s second claim for negligent misrepresentation and claims for breach of warranty and reformation under Rule 12(b)(6). Dkt. 55. The District Court denied the motion as to Homeland’s claim for declaratory relief that there was no coverage under the policy. Id.

On May 26, 2021, Homeland filed a Motion for Leave to File a Second Amended Complaint to (1) amend its claims for declaratory relief and negligent misrepresentation to include additional Irish CervicalCheck claims “that Defendants have noticed to Homeland since the filing of Homeland’s first amended complaint”; (2) add a promissory estoppel claim; (3) “add allegations that make clear that the 2016 Warranty Letter was incorporated into the 2016 policies”; and (4) add an allegation that the 2017 Policy was a renewal of the 2016 Policy. Dkt. 34 at 2-3. The District Court granted the Motion for Leave except as to the negligent misrepresentation claim, which the

2 For a summary of the factual background, see the Report and Recommendation of the United States Magistrate Judge issued July 19, 2022, Dkt. 112 at 2-7. Court had dismissed with prejudice. Dkt. 54 at 5. On August 17, 2021, Homeland filed its 57-page Second Amended Complaint against CPL and Sonic USA, which is its operative complaint. Dkt. 56. CPL asserts several counterclaims against Homeland, including breach of contract, anticipatory breach of contract, bad faith under the Texas Insurance Code, and a claim for

attorneys’ fees. Dkt. 46. Homeland has asserted twenty affirmative defenses to CPL’s counterclaims. Dkt. 53 at 44-53. On October 14, 2021, Defendants filed a Motion for Summary Judgment on all affirmative claims for relief asserted in Homeland’s Second Amended Complaint and on several affirmative defenses in Homeland’s Amended Answer. Dkt. 63. In its Response, Homeland argued for the first time that the “fortuity doctrine” bars all coverage in this case because Defendants were aware of potential claims against them before they sought and obtained a Worldwide Territory Endorsement extending coverage to claims filed against Defendants outside the United States. Dkt. 73 at 11-12. On July 19, 2022, the undersigned Magistrate Judge issued a Report and Recommendation that

the District Court grant Defendants’ Motion for Summary Judgment as to Homeland’s breach of warranty, promissory estoppel, and first reformation claims; Homeland’s prior notice exclusion affirmative defense; and Defendants’ request that defense costs incurred in defending the ICC claims do not erode policy limits under the 2017 Policy. Dkt. 112 at 30. The Court further recommended that the District Court deny Defendants’ Motion for Summary Judgment as to Homeland’s claims for declaratory relief and second reformation claim, as well as Homeland’s prior knowledge exclusion and misrepresentation affirmative defenses. Id. Relevant here, the Court also found that Homeland had waived its fortuity doctrine defense by failing to assert the defense in its Second Amended Complaint or as an affirmative defense in its Amended Answer, as required under Rule 8(c). “Based on the specific facts of this case, the Court finds that Homeland’s delay in raising the fortuity defense constitutes unfair surprise.” Id. at 15. The Court pointed out that Homeland had filed a Motion for Leave to File Second Amended Complaint some ten months earlier, on May 26, 2021, to add four additional claims, but failed to seek leave to assert the fortuity doctrine defense. Id. Accordingly, the Court concluded that

“allowing Homeland to assert the fortuity doctrine at this late date constitutes unfair surprise that would prejudice Defendants.” Id. Both parties filed objections to the Report and Recommendation. In its Objection, Homeland argued that the Court’s finding that Homeland had waived the fortuity doctrine defense was “Contrary To The Law and Unsupported by Fact.” Dkt. 126 at 2. On September 29, 2022, the District Court adopted the Report and Recommendation in full. Dkt. 149. Homeland now seeks leave under Rule 15(a) to file a Third Amended Complaint to add the fortuity doctrine defense. Dkt. 131 at 2. Defendants oppose the Motion, arguing that Homeland has failed to demonstrate good cause under Rule 16(b) to file a third amended complaint.

Free access — add to your briefcase to read the full text and ask questions with AI

Homeland Insurance Company of New York v. Clinical Pathology Laboratories, Inc., (W.D. Tex. 2022).

Homeland Insurance Company of New York v. Clinical Pathology Laboratories, Inc. (Homeland Insurance Company of New York v. Clinical Pathology Laboratories, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related